Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
New England Journal of MedicinePublished 16 February 2005Open access
Robert S. Bresalier, Robert S. Sandler, Hui Quan, James A. Bolognese, Bettina Oxenius, Kevin Horgan
Citations2,487
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.
Abstract
Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
New England Journal of MedicineComparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
4,017 Citations2000Claire Bombardier, Loren Laine +10 more
In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
BMJCollaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
3,125 Citations1994Antiplatelet Trialists' Collaboration
There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events, so in each of the four main high risk categories overall mortality was significantly reduced.
New England Journal of MedicineCardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
2,054 Citations2005Scott D. Solomon, John J.V. McMurray +8 more
New England Journal of MedicineThe Coxibs, Selective Inhibitors of Cyclooxygenase-2
1,555 Citations2001Garret A. FitzGerald, Carlo Patrono
Development of the coxibs, a new group of antiinflammatory drugs, represents a response to the unsatisfactory therapeutic profile of NSAIDs.
New England Journal of MedicineA Randomized Trial of Aspirin to Prevent Colorectal Adenomas
1,425 Citations2003John A. Baron, Bernard F. Cole +22 more
Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel, using generalized linear models to compute risk ratios and 95 percent confidence intervals.
Proceedings of the National Academy of SciencesSystemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
1,308 Citations1999Brendan McAdam, Francesca Catella-Lawson +4 more
New England Journal of MedicineComplications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
1,094 Citations2005Nancy A. Nussmeier, Andrew Whelton +6 more
The use of parecoxib and valdecoxib after CABG was associated with an increased incidence of cardiovascular events, arousing serious concern about the use of these drugs in such circumstances.
The LancetRisk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study
908 Citations2005David J. Graham, David Campen +6 more
Rofecoxib use increases the risk of serious coronary heart disease compared with celecoxib use, and naproxen use does not protect against serious coronaryHeart disease.
The LancetRisk of cardiovascular events and rofecoxib: cumulative meta-analysis
838 Citations2004Peter Jüni, Linda Nartey +4 more
The findings indicate that rofecoxib should have been withdrawn several years earlier and the reasons why manufacturer and drug licensing authorities did not continuously monitor and summarise the accumulating evidence need to be clarified.
The LancetCOX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
508 Citations2002Wayne A. Ray, Christoph Stein +4 more
A retrospective cohort study of individuals on the expanded Tennessee Medicaid programme (TennCare), in which occurrence of serious coronary heart disease (CHD) in non-users and in users of rofecoxib and other NSAIDs is assessed.
CirculationRelationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
506 Citations2004Daniel H. Solomon, Sebastian Schneeweiß +5 more
Current rofecoxib use was associated with an elevated relative risk of AMI compared with celecoxib use and no NSAID use, and Dosages of rofECoxib >25 mg were associated with a higher risk than dosages ≤25 mg, which was elevated in the first 90 days of use but not thereafter.
The LancetComparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
489 Citations2004Michael E. Farkouh, Howard S. Kirshner +16 more
The primary endpoint, including incidence of myocardial infarction, did not differ between lumiracoxib and either ibuprofen or naproxen, irrespective of aspirin use, suggesting that lumirACoxib is an appropriate treatment for patients with osteoarthritis, who are often at high cardiovascular risk and taking low-dose aspirin.
Cancer CellTargeting cyclooxygenase-2 in human neoplasia
446 Citations2003Andrew J. Dannenberg, Kotha Subbaramaiah
This paper presents a meta-analyses of the response of the immune system to various types of chemotherapy treatments and shows clear patterns of decline in the number of immune-related adverse events and in the severity of these events.
The LancetCyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study
434 Citations2004Muhammad Mamdani, David N. Juurlink +7 more
Findings suggest a higher risk of admission for congestive heart failure in users of rofecoxib and non-selective NSAIDs, but not celecoxib, relative to non-NSAID controls.
CirculationCardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
355 Citations2001Marvin A. Konstam, Matthew R. Weir +5 more
This analysis provides no evidence for an excess of CV events for rofecoxib relative to either placebo or the non-naproxen NSAIDs that were studied.
American Journal of TherapeuticsCyclooxygenase-2???Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients
334 Citations2001Andrew Whelton, John G. Fort +4 more
Patients taking antihypertensive therapy and receiving cyclooxygenase-2–specific inhibitors should be monitored for the development of cardiorenal events.
The American Journal of CardiologyEffects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis
307 Citations2002Andrew Whelton, William B. White +3 more
In patients with controlled hypertension on a fixed antihypertensive regimen, careful monitoring of BP is warranted after the initiation of celecoxib or rofecoxib therapy.
Arthritis & RheumatismBasic biology and clinical application of specific cyclooxygenase-2 inhibitors
294 Citations2000Leslie J. Crofford, Peter E. Lipsky +4 more
Clinical trials demonstrate the potential for clinically meaningful reductions in the incidence of the most serious GI complications found with nonselective NSAIDs, i.e., ulcer, perforation, and GI bleeding.
Archives of Internal MedicineEffect of Selective Cyclooxygenase 2 Inhibitors and Naproxen on Short-term Risk of Acute Myocardial Infarction in the Elderly
284 Citations2003Muhammad Mamdani, Paula A. Rochon +6 more
The findings of this observational study suggest no increase in the short-term risk of AMI among users of selective cyclooxygenase 2 inhibitors as commonly used in clinical practice and do not support a short- term reduced risk ofAMI with naproxen.
Archives of Internal MedicineLower Risk of Thromboembolic Cardiovascular Events With Naproxen Among Patients With Rheumatoid Arthritis
237 Citations2002Douglas J. Watson, Thomas Rhodes +2 more
Patients with rheumatoid arthritis and a current prescription for naproxen had a reduced risk of acute major TCEs relative to those with noNaproxen prescription in the past year, consistent with the ability of naproxens to inhibit platelet aggregation.
Archives of Internal MedicineNonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction
233 Citations2002Daniel H. Solomon, Robert J. Glynn +2 more
Although NSAIDs have anti-inflammatory and antiplatelet effects similar to those of aspirin, it was found that these drugs confer a protective effect against AMI, and use of one specific NSAID, naproxen, appeared to be associated with a reduced rate of AMI.
Annals of Internal MedicinePatients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
224 Citations2005Stephen E. Kimmel, Jesse A. Berlin +5 more
A casecontrol study from 36 hospitals in a 5-county area found that reported recent use of a COX-2 selective inhibitor was similar among adults with a first, nonfatal myocardial infarction (MI) and randomly selected community controls with no history of MI, however, reported use of rofecoxib was associated with a higher odds of MI than was use of celecoxib.
Archives of Internal MedicineAssociation Between Naproxen Use and Protection Against Acute Myocardial Infarction
203 Citations2002Elham Rahme, Louise Pilote +1 more
Compared with other NSAIDs, concurrent exposure to naproxen has a protective effect against acute myocardial infarction (AMI).
CirculationCyclooxygenases, Thromboxane, and Atherosclerosis
193 Citations2005Karine Egan, Miao Wang +5 more
TP antagonism is more effective than combined inhibition of COX-1 and COx-2 in retarding atherogenesis in Apobec-1/LDLR DKO mice, which perhaps reflects activation of the receptor by multiple ligands during disease initiation and early progression.
The American Journal of CardiologyComparison of cardiovascular thrombotic events in patients with osteoarthritis treated with Rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (Ibuprofen, Diclofenac, and Nabumetone)
138 Citations2002Alise Reicin, Deborah R. Shapiro +3 more
There was no difference between rofecoxib, comparator nonselective NSAIDs, and placebo in the risks of cardiovascular thrombotic events in the rofECoxib osteoarthritis development program, and similar rates of APTC events were reported.
American Heart JournalSelective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program
122 Citations2003Matthew R. Weir, Rhoda Sperling +2 more
A pooled analysis from 23 studies encompassing multiple disease states and including more than 14,000 patient-years at risk demonstrated that rofecoxib was not associated with excess CV thrombotic events compared with either placebo or nonnaproxen NSAIDs.
Journal of the American College of CardiologyNonsteroidal Anti-Inflammatory drugs and cardiovascular risk
120 Citations2004Patricia Howard, Patrice Delafontaine
Nonsteroidal anti-inflammatory drugs (NSAID) inhibit cyclooxygenase (COX) enzymes, which exist in at least two isoforms, COX-1 andCOX-2, and it is becoming increasingly clear that understanding of the role of COx-2 in cardiovascular function is incomplete.
Arthritis Care & ResearchThe risk of cardiovascular thrombotic events with selective cyclooxygenase‐2 inhibitors
77 Citations2002Vibeke Strand, Marc C. Hochberg
Two large outcome trials were designed to demonstrate GI safety superior to that of traditional NSAIDs, as used in regular clinical practice, assessed by “clinically meaningful” upper GI events, at twice recommended clinical doses for long-term use.
American Journal of EpidemiologyEXACT BINOMIAL CONFIDENCE INTERVALS FOR THE RELATIVE RISK IN FOLLOW-UP STUDIES WITH SPARSELY STRATIFIED INCIDENCE DENSITY DATA1
51 Citations1987Harry A. Guess, Eva Lydick +2 more
A computer program for hypothesis testing and calculation of exact binomial confidence intervals for the adjusted relative risk in follow-up studies involving multiple strata with incidence density ( person-time) denominators and small or zero person-count numerators is presented.
Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients
32 Citations2002Andrew Whelton, John G. Fort +4 more